Enrique Alvarez

Enrique Alvarez

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
DCDavid B. Clifford
David B. Clifford
KTKenneth Tyler
Kenneth Tyler
BABeau Ances
Beau Ances
CCCraig Costello
Craig Costello
SRShari Rosen-Schmidt
Shari Rosen-Schmidt
KTKenneth L. Tyler
Kenneth L. Tyler
Objective: To describe the development of progressive multifocal leukoencephalopathy (PML) in patients with rheumatoid arthritis (RA) treated with rituximab.Design: Case study.Setting: Clinical care for patients with rheumatologic diseases. Most were referred to academic centers for care after diagnosis (Washington University, St Louis, Missouri; Karolinska Insitute, Stockholm, Sweden; and Royal Melbourne Hospital, Melbourne, Australia) while one was cared for in a neurology practice in Dallas, Texas, with consultation by an academic neurovirologist from the University of Colorado in Denver.Patients: Four patients developing PML in the setting of rituximab therapy for RA.Intervention: Rituximab therapy.Main Outcome Measures: Clinical and pathological observations.Results: Four patients from an estimated population of 129 000 exposed to rituximab therapy for RA are reported in whom PML developed after administration of this drug. All were women older than 50 years, commonly with Sjögren syndrome and a history of treatment for joint disease ranging from 3 to 14 years. One case had no prior biologic and minimal immunosuppressive therapy. Progressive multifocal leukoencephalopathy presented as a progressive neurological disorder, with diagnosis confirmed by detection of JC virus DNA in the cerebrospinal fluid or brain biopsy specimen. Two patients died in less than 1 year from PML diagnosis, while 2 remain alive after treatment withdrawal. Magnetic resonance scans and tissue evaluation confirmed the frequent development of inflammatory PML during the course of the disease.Conclusion: These cases suggest an increased risk, about 1 case per 25 000 individuals, of PML in patients with RA being treated with rituximab. Inflammatory PML may occur in this setting even while CD20 counts remain low.

1 May 2002 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
DCDaniel A. Clayton
Daniel A. Clayton
MMMichael H. Mesches
Michael H. Mesches
EAEnrique Alvarez
Enrique Alvarez
PBPaula Bickford
Paula Bickford
MBMichael D. Browning
Michael D. Browning
Aged rats are known to have deficits in spatial learning behavior in the Morris water maze. We have found that aged rats also have deficits in NR2B protein expression and that the protein expression deficit is correlated with their performance in the Morris water maze. To test whether this NR2B deficit was sufficient to account for the behavioral deficit, we used antisense oligonucleotides to specifically knock down NR2B subunit expression in the hippocampus of young rats. NR2B antisense treatment diminished NMDA receptor responses, abolished NMDA-dependent long-term potentiation (LTP), and impaired spatial learning. These data demonstrate the important role of NR2B in LTP and learning and memory and suggest a role for reduced NR2B expression in age-related cognitive decline.

1 May 2011 in Neurologic Clinics
Verified
Journal Article
Closed access
GWGregory F Wu
Gregory F Wu
EAEnrique Alvarez
Enrique Alvarez

28 September 2021 in Neurorehabilitation and Neural Repair
Verified
Journal Article
Closed access
PDF file
RERoger M. Enoka
Roger M. Enoka
AAawad almuklass
awad almuklass
MAMohammed Alenazy
Mohammed Alenazy
EAEnrique Alvarez
Enrique Alvarez
JDJacques Duchateau
Jacques Duchateau
Fatigue is one of the most common debilitating symptoms reported by persons with multiple sclerosis (MS). It reflects feelings of tiredness, lack of energy, low motivation, and difficulty in concentrating. It can be measured at a specific instant in time as a perception that arises from interoceptive networks involved in the regulation of homeostasis. Such ratings indicate the state level of fatigue and likely reflect an inability to correct deviations from a balanced homeostatic state. In contrast, the trait level of fatigue is quantified in terms of work capacity (fatigability), which can be either estimated (perceived fatigability) or measured (objective fatigability). Clinically, fatigue is most often quantified with questionnaires that require respondents to estimate their past capacity to perform several cognitive, physical, and psychosocial tasks. These retrospective estimates provide a measure of perceived fatigability. In contrast, the change in an outcome variable during the actual performance of a task provides an objective measure of fatigability. Perceived and objective fatigability do not assess the same underlying construct. Persons with MS who report elevated trait levels of fatigue exhibit deficits in interoceptive networks (insula and dorsal anterior cingulate cortex), including increased functional connectivity during challenging tasks. The state and trait levels of fatigue reported by an individual can be modulated by reward and pain pathways. Understanding the distinction between fatigue and fatigability is critical for the development of effective strategies to reduce the burden of the symptom for individuals with MS.

15 January 2013 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
EAEnrique Alvarez
Enrique Alvarez
LPLaura Piccio
Laura Piccio
RMRobert J Mikesell
Robert J Mikesell
EKEric C Klawiter
Eric C Klawiter
BPBecky J Parks
Becky J Parks
ACAnne H Cross
Anne H Cross
CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optica and IgG index in multiple sclerosis. Additionally, serum CXCL13 was elevated in neuromyelitis optica.

1 September 2004 in Stem Cells
Verified
Journal Article
Closed access
KBKimberley A. Buytaert‐Hoefen
Kimberley A. Buytaert‐Hoefen
EAEnrique Alvarez
Enrique Alvarez
CFCurt R. Freed
Curt R. Freed
Tyrosine hydroxylase (TH)-positive neurons were generated from human embryonic stem (hES) cells by coculturing on astrocytes or PA6 stromal cells. After 3 to 4 weeks in culture, TH-positive cells with neuronal morphology developed. Coculture with astrocytes from the embryonic striatum produced a larger number of TH-positive cells than did coculture with astrocytes from embryonic mesencephalon (329 +/- 149 versus 33 +/- 16 TH-positive cells per well, p < .05). In other experiments using PA6 cells as a substrate, glial-derived neurotrophic factor (GDNF) was added to the media of differentiating hES cells, and this led to a doubling of the number of TH-positive cells (PA6: 443 +/- 105 TH-positive cells per well versus PA6 + GDNF: 934 +/- 136, p < .05). We conclude that substrates of striatal astrocytes and PA6 cells can promote differentiation of human embryonic stem cells to a TH-positive phenotype and that GDNF can increase the number of cells expressing that phenotype.